Informations

Upper tract urothelial carcinoma (UTUC) is an aggressive malignancy of the urinary system, with high-risk subtypes associated with substantial risks of recurrence, metastasis, and poor prognosis. For decades, radical nephroureterectomy has been the standard treatment for high-risk UTUC. However, this approach inevitably leads to irreversible renal function impairment and may even result in renal failure,…

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings…

With ongoing advances in research, combinations of targeted therapy and immunotherapy have become the standard first-line treatment for advanced urothelial carcinoma. However, upper tract urothelial carcinoma (UTUC) differs significantly from bladder cancer in terms of anatomical structure, pathological characteristics, prognosis, and recurrence risk. As a result, radical nephroureterectomy (RNU) remains the gold standard for non-metastatic…

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. As one of the premier global academic meetings in genitourinary oncology, the conference showcased multiple landmark studies that are reshaping clinical practice worldwide.

As hematologic malignancy treatment advances toward precision medicine and cellular therapy, relapsed/refractory mixed phenotype acute leukemia (MPAL) remains a major clinical challenge due to its rarity and aggressive nature.

At the 52nd EBMT Annual Meeting held in Madrid in March 2026, the team led by Prof. Zhang Yajing presented a novel therapeutic approach targeting one of the most challenging clinical scenarios in hematology—early relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Non–muscle-invasive bladder cancer (NMIBC) carries a substantial risk of postoperative recurrence, particularly in high-risk and very high-risk patients, where the 5-year recurrence rate can exceed 50%. In recent years, beyond traditional Bacillus Calmette–Guérin (BCG) intravesical therapy, the emergence of immune checkpoint inhibitors (ICIs) and antibody–drug conjugates (ADCs) has provided new therapeutic options to reduce recurrence…

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. Numerous landmark studies in genitourinary oncology were presented, providing key evidence to inform and refine clinical practice. Among them, the phase II randomized CYTOSHRINK trial, focusing on treatment-naïve advanced renal cell carcinoma, reported its latest findings, offering important insights…